CHMP Backs Hansoh Pharma’s Aumolertinib – China’s First Homegrown Third‑Generation EGFR‑TKI Recommended for EU Approval in NSCLC

Fineline Cube
3 Min Read
Summarize with AI

Hansoh Pharmaceutical Group (HKG: 3692) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of aumolertinib (overseas trade name: Aumseqa) for the treatment of non‑small cell lung cancer (NSCLC). The recommendation marks a milestone for China’s first domestically developed third‑generation EGFR‑TKI, positioning Hansoh Pharma to bring a homegrown oncology innovation to the European market.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyCHMP / EMA (European Union)
Opinion TypePositive opinion recommending marketing authorization
ProductAumolertinib (EU trade name: Aumseqa)
IndicationTreatment of non‑small cell lung cancer (NSCLC)
ClassThird‑generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) – China’s first domestically developed in class
Announcement Date15 November 2026
Next StepsEuropean Commission final decision on marketing authorization following the CHMP opinion

Drug Profile & Mechanism of Action

  • Molecule: Aumolertinib – China’s first domestically developed third‑generation EGFR‑TKI, targeting EGFR mutations in NSCLC.
  • Physicochemical Design: Features high lipophilicity and stability, enabling enhanced blood‑brain barrier penetration – a critical attribute given the high incidence of central nervous system metastases in advanced EGFR‑mutated NSCLC.
  • Safety Profile: Demonstrates a low incidence of adverse events, supporting long‑term daily dosing in early‑stage adjuvant through advanced‑disease settings.
  • China Approval History: Initially approved in March 2020; all four approved indications are included in China’s National Reimbursement Drug List (NRDL).

Approved Indications in China (All NRDL‑Covered)

  • Adjuvant therapy following tumor resection in patients with EGFR‑mutated NSCLC
  • Maintenance therapy after chemoradiotherapy in patients with unresectable locally advanced NSCLC
  • First‑line treatment for advanced NSCLC
  • Second‑line treatment for advanced NSCLC

Market Impact & Outlook

  • Globalization Milestone: The CHMP positive opinion advances aumolertinib toward becoming one of the first China‑originated third‑generation EGFR‑TKIs authorized in the EU – a symbolic and commercial breakthrough for Chinese innovative oncology on the global stage.
  • CNS Penetration Edge: Enhanced blood‑brain barrier penetration positions Aumseqa competitively in the EU third‑generation EGFR‑TKI market, where CNS efficacy is a key differentiator in treatment selection.
  • Reimbursement Track Record: Full NRDL coverage of all four indications in China since initial approval in March 2020 underscores broad clinical adoption and provides a substantial real‑world evidence base supporting the EU filing.
  • Portfolio Strategy: The EU expansion complements Hansoh Pharma’s recent AI‑driven discovery partnerships and reinforces its trajectory from domestic leader to global innovator, with regulatory submissions in additional regions a potential next step.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review of aumolertinib (Aumseqa), the anticipated European Commission decision following the CHMP opinion, commercialization plans in the EU, and pipeline expectations. Actual results may differ due to risks including final regulatory determinations, market adoption, reimbursement negotiations, clinical outcomes, and competitive dynamics.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *